Childhood cancer survival in Navarra remains at 80% thanks to personalised treatments

14 de February de 2024

In 2023,
the Multidisciplinary Unit for Child and Adolescent Cancer (UMDCIA) at the
University Hospital of Navarra diagnosed 22 new cases of cancer in patients
aged between 1 month and 16 years, maintaining the figure of care at 44
children, similar to previous years. The overall survival rate remains at
around 80%, stabilised thanks to personalised treatments and the inclusion of
patients in clinical trials to test new drugs specifically targeting tumour
cells. This approach aims not only to increase survival but also to reduce
long-term side effects.

lymphoblastic leukaemia (ALL) was the most commonly diagnosed tumour in 2023,
accounting for 25% of cases, followed by brain tumours with 20%. Other
diagnoses include non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, neuroblastoma,
myeloid leukaemia, and sarcomas, among others.

Multidisciplinary care for each case
active since July 2021, provides a multidisciplinary approach to the treatment
and follow-up of these diseases, involving paediatric oncologists, specialist
nurses and professionals from various medical specialties. In the last five
years, the University Hospital of Navarra has diagnosed 108 cases of childhood
cancer, with a progressive increase in cases since 2019. The follow-up
consultation for survivors sees 40 patients a month, adapting the frequency of
visits to the type of tumour and preparing the transition to adult units when
Skip to content